Wednesday, 10 August 2022

Natco launches anticoagulant tablet Rivaroxaban in India

18 December 2020 | News

Rivaroxaban is currently sold by Bayer under brand name of Xarelto® in the Indian market

Source credit: Shutterstock

Source credit: Shutterstock

Natco Pharma Limited has announced the launch of Rivaroxaban molecule, under brand RPIGAT.

Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots. Rivaroxaban is currently sold by Bayer under brand name of Xarelto®, in the Indian market.

After successful previous launches of DABIGAT (Dabigatran) and AP IGAT (Apixaban) by NATCO, this latest Rivaroxaban NOAC (Novel oral anti-coagulant) is in line with the Company’s mission of affordable medicines accessible to all.

NATCO has launched RPIGAT in four strengths- 20 mg, 15 mg, 10 mg and 2.5 mg. The 20 mg strength is priced at an MRP of Rs 14.0 per tablet.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account